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MONOCLONAL ANTIBODIES promise to
revolutionize our ability to define and
analyse the molecular components of
tumour cell surfaces. To date these anti-
bodies have been of mouse or rat origin.
Here we report the production of human
monoclonal antibodies by the fusion of
intratumoral lymphocytes from a patient
with a malignant glioma and a mouse
myeloma line. Four such antibodies were
found to bind to determinants present on
the patient's own glioma cell membranes
and not to normal brain tissue. Although
the molecularnature ofthese determinants
remain unclear, they may well be tumour-
related neoantigens appearing on glioma
cells.
A 35-year-old woman presenting with
grand mal fits was found to have a poorly
differentiated oligodendroglioma in the
right frontal region. Thebulkofthetumour
was removed at craniotomy and a course
of post-operative radiotherapy given. She
was well for 2 years, but then developed a
local recurrence of tumour. Repeat ex-
cision was performed and followed by
chemotherapy with CCNU. She died 6
months after the second excision, with
persistent disease.
Two grams of fresh tumour tissue from
the second operation was cut with fine
scissors and teased apart in tissue-culture
medium (Dulbecco's modification of
Eagle's medium, 20% foetal calf serum,
penicillin 100 i.u./ml and streptomycin
100-200 mg/ml). The resulting cell suspen-
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sion was layered on to Ficoll-Hypaque
and centrifuged at 400 g for 30 min. Cells
collecting at the interface were harvested
and washed x 3. This preparation con-
sisted of lymphocytes and macrophages
together with some tumour cells. 108 of
such cells were mixed with 2 x 107 P3
NSI/lAg 4.1 mouse myeloma cells and
fused in polyethylene glycol using tech-
niques described elsewhere (Levy & Dilley,
1978). After fusion the resultant cells were
distributed in two 24-well Linbro tissue
culture plates (Cat. No. 76-603305) and
incubated in tissue culture medium con-
taining hypoxanthine, aminopterin and
thymidine. This permits the growth ofany
human lymphocyte-mouse myeloma hy-
brid cells but not the mouse myeloma.
After 3 weeks, hybrid colonies were seen
in mostwells. These wereclonedbymaking
serial doubling dilutions of each well into
6 further wells. The supernatants were
harvested from wells containing single
hybrids and tested for the presence of
human immunoglobulin using a solid-
phase radioimmunoassay (Sikora et al.,
1979). 18 out of 48 supernatants con-
tained human immunoglobulin. These
were tested further for binding activity to
immobilized cell membranes prepared
from the patient's own glioma cells, and
on a membrane preparation from pooled
normal brain tissue. Fresh tumour or
tissue was chopped finely in cold PBS and
washed x 3 before being suspended in
hypotonic buffer (0O01M Tris HCl with
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OOlmM PMSF). After 30 min at 4°C the
tissue was homogenized using a Dounce
press. The homogenate was layered on to
45% sucrose and spun for 1 h at 40,000
rev/min in an ultracentrifuge. The mem-
brane fraction which layered on top ofthe
sucrose was harvested and dialysed over-
night against PBS containing OOlmM
PMSF. The membrane preparation was
subjected to 3 x 20-second pulses of ultra-
sound (amplitude 12 ,m peakto peak) and
adjusted to a concentration of 0 3 O.D.
units/ml at 280 um. 50 ,il of this prepara-
tion was added to each well of a vinyl
microtitre plate and incubated overnight
at 4°C. After washing in PBS containing
2% BSA, 50 ,ul of each supernatant was
added for 1 h in triplicate. After further
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FIGURE.-Radioimmunoassay showing bind-
ing ofhumanimmunoglobulins produced by
mouse human hybrids to normal brain cell
membranes and to membranes prepared
from glioma cells.
washing, the assay was developed using a
radioiodinated rabbit anti-human im-
munoglobulin. Each well was counted
after washing using a gamma counter.
Of the 18 immunoglobulins, none were
found to bind significantly to the normal
brain membranes. Four, however, bound
to immobilized membranes from the
patient's own tumour (Figure). Eight
weeks after fusion, all 18 of the hybrid
clones tested ceased human Ig production.
The demonstration that human Igs are
produced by the fusion of intratumoral
lymphocytes from a patient with malig-
nant glioma and mouse myeloma cells
provides evidence for the presence within
the glioma of functioning B lymphocytes.
In addition, the recognition of glioma
membrane components by 4 of these
monoclonal products indicates that the
human immune system is able to dis-
criminate between glioma and normal
brain cell surfaces.
The possibility of neoantigens on
gliomas is supported by other experi-
mental evidence for the existence of
tumour antigens on established glioma
cells lines (Wahlstrom et al., 1974).
Furthermore, that B lymphocytes may be
part of a lymphoid response to glioma is
supported by the recent discovery of a
heterogeneous (large and small cells) popu-
lation of cells with receptors for Fc (IgG),
complement components (C3) and surface
immunoglobulin (slg) in gliomas and
normal brain (Phillips et at., 1981).
It is of interest that the patient in this
study survived for 22 years despite
having an anaplastic oligodendroglioma.
The histological finding of definite peri-
vascular lymphocytic cuffingwith vascular
proliferation in this tumour is in keeping
with current evidence of an attempted
host response in these patients. By using
a panel of gliomas and other tumours we
hope to further characterize the neo-
antigens on this tumour and the nature of
the immune response to them. It was dis-
appointing that the hybrids lost their
human-Ig-secreting capability within 8
weeks of fusion. This was most likely due
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to segregation of human chromosomes.
Because of this, insufficient quantities of
monoclonal antibodies could be obtained
to explore their therapeutic potential. We
are currently investigating methods of
obtaining stable human Ig-producing
hybrids.
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